Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

Status Recruiting

Clinical Trial Summary

This study will collect bone marrow (BM) aspirate samples from patients with relapsed refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker of patient response to that regimen. The primary study objective is to explore whether the single-cell MAR biomarker can predict patient response in RRMM patients. In order to enable this primary objective, two patient cohorts will be required. First, a small vanguard cohort of patients with treatment naïve disease to define drug concentrations used for testing, and second, the main RRMM patient cohort. Data will be collected to estimate the biomarker's predictive properties (accuracy, sensitivity, specificity), and to support improvement of the MAR biomarker through additional research and discovery within the study dataset.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03777410
Study type	Observational
Source	Travera Inc
Contact	Mark Stevens, Ph.D.
Phone	6172999784
Email	RRMMStudy@travera.com
Status	Recruiting
Phase
Start date	February 11, 2019
Completion date	January 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01435720` - Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)	Phase 1/Phase 2
Recruiting	`NCT04094961` - Ixazomib + Pomalidomide + Dexamethasone In MM	Phase 1/Phase 2
Recruiting	`NCT06068400` - Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma	N/A
Recruiting	`NCT03601624` - Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans	Phase 2
Recruiting	`NCT05020444` - TriPRIL CAR T Cells in Multiple Myeloma	Phase 1
Not yet recruiting	`NCT03706547` - Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM	Phase 1
Active, not recruiting	`NCT02970747` - Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
Not yet recruiting	`NCT06411301` - A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors	Phase 1
Completed	`NCT01965353` - A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma	Phase 1
Not yet recruiting	`NCT05581875` - A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory	Phase 1/Phase 2
Terminated	`NCT03687125` - Tinostamustine Conditioning and Autologous Stem Cell	Phase 1/Phase 2
Recruiting	`NCT06282978` - Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes	Phase 2
Recruiting	`NCT06158412` - All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma	Phase 2
Active, not recruiting	`NCT03030261` - Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma	Phase 2
Recruiting	`NCT04925193` - Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma	Phase 2
Recruiting	`NCT05121103` - A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma	Phase 1
Recruiting	`NCT04603872` - CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies	Early Phase 1
Recruiting	`NCT04657861` - APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma	Early Phase 1
Terminated	`NCT05191472` - Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies	Phase 2
Completed	`NCT03136653` - A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma	Phase 1/Phase 2